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Oikonomou et al. [1] concluded that Galectin-3 (Gal-3) is a novel marker of 
chronic kidney disease with predictive ability in decompensated cirrhosis and 
an index of disease outcome. Notably, although the relationship between 
plasma concentrations of Gal-3 and estimated glomerular filtration rate 
(eGFR) is well established [2], a similar association in a cohort of patients with 
liver cirrhosis has not been studied so far. In this regard, Helicobacter pylori 
infection (Hp-I) is linked with Gal-3 overexpression [3] and appears to be a 
common denomina- tor of liver cirrhosis, in the context of viral hepatitis, non-
alcoholic fatty liver disease (NAFLD), also studied by the authors, and renal 
insufficiency. For instance, as in the case of NAFLD, Hp-I is highly prevalent 
globally [its current prevalence is 58% (39.9%–84.2%) with increasing 
tendency due to the effect of immigration] and we postulated that the Hp-I 
might contribute to pathogenesis of NALFD, whereas its eradication may 
attenuate NAFLD development and/or progression towards advanced liver 
disease [4]. Moreover, Hp-I is strongly associated with hepatitis B- and C-
related cirrho- sis in Europe and in other ethnic populations and Hp 
eradication is advocated as a promising approach for the long-term over- all 
health improvement in patients with chronic viral infection [5]. With respect to 
Hp-I in patients with chronic renal disease, although literature appears 
conflicting, recent studies demon- strate a connection between Hp-I and end-
stage renal disease [6]. Existing evidence so far underlines the role of 
increased serum Gal-3 as an indicator of renal function in patients with heart 
failure. In this respect, Hp-mediated inflammation has been linked with 
atherosclerosis and the early events of coronary vascular syndrome, thereby 
influencing the development and/or the progression of cerebro-cardiovascular 
disease (C-CVD) and suggesting eradication therapy for prevention. Hp 
eradication might display a positive impact on Hp-related chronic viral 
infection associated with NAFLD and CVD development/progression [5]. 
Moreover, there is growing evidence indicating a connection between Hp-I 
and insulin resis- tance (IR) syndrome or metabolic syndrome (MetS) and its 
related morbidity, including NAFLD and C-CVD, the latter being the end- 
points of MetS [7]. In our series we demonstrated that increased fibrinogen 
lev- els (an independent risk factor for CVD) are associated with Hp-I and can 
be significantly reduced by Hp eradication. Several mech- anisms mediated 
by Hp may be implicated in the perceived risk of CVD. For instance, beyond 
its role in IR or in increasing fibrino- gen, Hp-I may promote coagulation by 
stimulating mononuclear cells towards the production of a tissue factor-like 
procoagulant activity that converts fibrinogen into fibrin; and promoting platelet 
aggregation via the binding of von Willebrand factor. Likewise, Hp-I may 
promote the formation of L- and P-selectin-dependent platelet–leukocyte 
aggregates. Moreover, Hp-I induces the expres- sion of plasminogen activator 
inhibitor-1, as well as increased plasma levels of triglycerides and various 
atherosclerotic risk fac- tors, such as homocysteine, involved in the 
pathogenesis of C-CVD [5,7]. Other pro-thrombotic mediators and mediators 
of atheroscle- rosis elevated in the context of Hp-I include the proinflammatory 
cytokines tumor necrosis factor (TNF)-฀ and interleukin (IL)-6, anticardiolipin 
antibodies and lipid peroxides, also associated with cardiovascular risk [7]. 
Likewise, serum Gal-3 is related with MetS parameters and has been 
proposed as an emerging biomarker of the overall risk of CVD [2], as it has 
been linked with myocar- dial fibrosis and inflammation; Gal-3 overexpression 
is responsible for the activation of fibroblasts and macrophages with the sub- 
sequent development of fibrosis, scar production and, eventually, of cardiac 
remodeling [2]. Elevated serum Gal-3 is also associated with a higher risk of 
all-cause mortality and more specifically with CVD mortality and heart failure; 
Gal-3 is an important predictor of mortality risk in patients with CVD, following 
adjustment for age and sex; and Gal-3 may also serve as a biomarker for the 
severity of CVD and renal dysfunction, as the two last disorders hav- ing been 
evaluated via measurements of brain natriuretic peptide (BNP) plus its N-
terminal part NT-proBNP and eGFR, respectively [2]. Moreover, Gal-3 has 
been stated to increase in ischemic brain damage [2]. Taken together, 
evidence suggests a potential role of Hp-related Gal-3 and MetS as mediators 
implicated in the chronic failure of var- ious organs, such as liver, heart, 
kidney and brain, and, thus further research is necessary. Regarding the Hp-
related Gal-3 involvement in brain disorders, also connected with liver 
cirrhosis, we recently reviewed the role of Gal-3 in Hp-related 
neuroinflammation and subsequent neu- rodegeneration [3]. Under conditions 
of neuroinflammation, Gal-3 mediates immune cell chemotactic recruitment in 
the central ner- vous system (CNS), a procedure also triggered by 
microorganisms, especially in the context of autoimmunity. Experimental 
evidence stemming from multiple sclerosis (MS) models indicates that Gal- 3 
may promote inflammatory infiltration in the CNS parenchyma upon disease 
exacerbation, a response particularly evident in the sub-ventricular zone, a 
physiological niche of adult neurogenesis [3]. Relative data also provide 
evidence of implication of Gal-3 sig- naling in models of traumatic brain injury, 
CNS neonatal hypoxia and prion disease, all conditions characterized by a 
strong neu- rodegenerative, and, to a lesser degree, inflammatory 
pathogenetic component. In this regard, an overall effect of Gal-3 in the 
cellular components of innate immunity may modulate CNS inflamma- tion 
and subsequent neurodegeneration [3]. Recent data indicate that Gal-3 is 
associated with increased risk of cognitive dysfunc- tion (CD), a disorder 
observed in the majority of patients with liver cirrhosis; Gal-3 is connected 
with poor prognosis of ischemic stroke; and Gal-3 induces amyloid-฀ (A฀) 
oligomerization and A฀ toxicity in Alzheimer’s disease (AD). Notably, 
neuropathol- ogy of hepatic encephalopathy (HE) in cirrhosis is principally of 
astroglial origin, classified as Alzheimer type 2 astrocytosis, and is further 
characterized by activation of microglia, suggestive of neuroinflammation. 
Regarding the Gal-3-mediated mechanisms involved in Hp- related 
neurodegeneration, it has been described that Hp-I is linked with Gal-3 
overexpression by macrophages, which results in reduced macrophage 
phagocytic capacity and persistent Hp gastric mucosa colonization [3]. Thus, 
the assumption that Gal-3 overexpression by the cells of the innate immunity 
contributes to the capacity of Hp to circumvent the host’s defense 
mechanisms is further supported. In this respect, gastric mucosa Gal-3 over- 
expression is a critical endogenous event in Hp-I that interferes with various 
intracellular processes, thereby prolonging cell sur- vival, a feature of gastric 
oncogenesis [2]. Moreover, one could hypothesize that cells or Hp epitopes 
stemming from the phago- cytosis of the bacterium and subsequent 
processing, may access CNS via blood-brain-barrier (BBB) disruption, 
intranasal inocula- tion or the fast retrograde vagal pathways [3]. In patients 
with Secondary Progressive MS, a disease type with prominent neurode- 
generative pathogenetic component, peripheral blood anti-Gal-3 antibodies 
recognize BBB structures. It is thus speculated that Gal-3 expressed by the 
BBB may act as an immunological target for autoimmune cells in MS, thus 
contributing to the patho- genesis of the disease. Moreover, Gal-3-related 
BBB disruption may provide brain access to other pathogenic mediators, such 
as Hp [3]. Hp might be further involved in BBB breakdown by releasing 
several proinflammatory/vasoactive mediators [8], such as TNF-฀ and IL-6, or 
even defensins, particularly those that display a unique distribution at BBB 
sites [9]. Hp may activate granulocytes and induce defensins release from 
granulo- cytes; subsequently, defensins, secreted by activated granulocytes, 
penetrate the BBB and gain access to the brain, thereby pos- sibly 
contributing to neurodegeneration. Taken together, these data support a 
combined role of Gal-3 in Hp-mediated neuroin- flammation and 
neurodegeneration. Overexpression of Gal-3 by gastric mucosa macrophages 
in the context of Hp-I may pro- vide molecular targets of structural similarity 
between epitopes expressed in the periphery, the BBB and the CNS, thus 
possibly triggering autoimmunity, neuroinflammation and, subsequently, 
neurodegeneration. We and others reported evidence of Hp-I association with 
CD, either in the context of liver cirrhosis and/or primary neurodegen- erative 
disease. We previously also reported an association of Hp-I with AD, mild 
cognitive impairment [8], MS or MS-related clini- cally isolated syndrome 
(CIS), as well as a favorable effect of Hp eradication towards increasing AD 
survival and delaying CIS pro- gression into definite MS. Hp-I is common in 
cirrhotic patients with HE and it appears to be a frequent denominator 
connected with CD-related falls and fractures, as well as with post-HE per- 
sistent CD in patients with liver cirrhosis [8]. Hepatitis C cirrhotic patients with 
detectable interferon-฀ and higher levels of IL-6 and TNF-฀ might be at risk of 
poor cognitive function. Hp-I may cause CD in the context of HE by: inducing 
hyperammonemia; promoting the release of proinflammatory and vasoactive 
sub- stances that further disrupt BBB; promoting platelet–leukocyte 
aggregation; and producing reactive oxygen metabolites or influ- encing 
apoptotic cellular processes [9]. Moreover, human defensins may contribute 
to Hp-related brain pathophysiology by modulating innate and adaptive 
immune responses. Specifically, human ฀- defensin-1 is upregulated in the 
context of Hp-I and may serve as a biomarker of bacterial translocation in 
cirrhotic patients, thus signi- fying Hp-related extragastric complications, such 
as CD and HE [10]. Of note, similarly to defensins, Gal-3 also displays 
antimicrobial activity [2]. In view of the aforementioned data, we hereby 
suggest that Hp-related Gal-3 connected with MetS may play a role in the 
pathophysiology of cirrhosis-related chronic kidney, cardiovascu- lar and brain 
disorders and, thus, further studies are warranted to elucidate this field, which 
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